In the past few years, the medical community has seen an increasing number of trials emerging for SGLT2 inhibitors and GLP-1 receptor agonist agents demonstrating positive results in reducing the risk for patients with cardiovascular disease and diabetes. The emergence of CV outcomes trials involving SGLT2 inhibitors identifying positive effect on CV mortality and reduction of heart failure has contributed to a paradigm shift to engage CV specialists to focus on comprehensive CV risk reduction beyond just glucose control for patients with T2D. The substantially higher risk in patients with both CV disease and diabetes combined with new advances in the field have contributed to growing interest in the intersection of these two highly prevalent diseases.

The goal of this page is to assemble the most salient resources to educate the CV community on the latest scientific developments in cardiovascular risk in diabetes and make this information easily accessible for greater adoption into clinical practice. This page has been curated with content focused on this topic and will be updated to include new developments as they are published. Education is needed to address the gaps in knowledge and lack of familiarity with emerging science behind the incorporation of medications into cardiology practice. In addition, as the role of cardiologists evolves with the use of SGLT2is and GLP-1RAs, there is a need for increased coordination and collaboration with PCPs and endocrinologists managing these high-risk patients. Sharing best practices from different perspectives and in various practice settings is critical to improving coordination of care among a multidisciplinary team.